Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited. The post Tryp Therapeutics To Be Acquired by Exopharm appeared first...
Newly issued patent expected to provide protection until at least 2041 and includes composition of matter claims to pharmaceutical compositions within...
Tryp Therapeutics Inc. (“Tryp” or the “Company“) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin...
The company is targeting a listing on the Australian Securities Exchange. The post Exopharm to Buy Tryp Therapeutics in All-Stock Deal appeared first on...
Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses. The...
Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of ibogaine derivative tabernanthalog. The post Terran...
New patent provides IP protection until at least 2041. Cybin’s patent portfolio now includes 39 granted patents and over 170 pending applications. The...
The soon-to-issue patent contains composition of matter and methods of use claims for a family of novel prodrug derivatives of psilocybin. The post Enveric...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
Philadelphia, November 2, 2023 – Major depressive disorder (MDD) is a widespread mental health condition that for many is disabling. It has long been...